Alchemia hits high for year

Investors hope the biotech will post its first profit for 2013-14 on growing royalty payments from its distribution partner Dr Reddy and its ongoing pipeline.

Biotech Alchemia (ACL) hit its highest level this year as investors buy into hopes that the current financial year would mark an important milestone for the company.

Alchemia is expected to post a maiden profit in 2013-14 thanks to growing royalty payments from its distribution partner Dr Reddy, which has licenced Alchemia’s technology to manufacture a generic anti-coagulant drug, fondaparinux.

The stock surged 9.3% to 47 cents this afternoon but the increasing royalty payments aren’t the only reason to warm to the stock, according to RBS Morgans.

The broker notes that the result for its phase 3 trial on a colon cancer drug treatment is expected in the June quarter next year and that the biotech’s fondaparinux could secure European regulatory approval.

RBS Morgans is urging investors to buy the stock and has a share price target of 71 cents a share.

Alchemia is the best performer on the Uncapped 100 this afternoon.

InvestSMART FORUM: Come and meet the team

We're loading up the van and going on tour from April to June, with events on the NSW central & north coast, the QLD mid-north coast and in Perth, Adelaide, Melbourne, Sydney and Canberra. Come and meet the team and take home simple strategies that you can use to build an investment portfolio to weather any storm. Book your spot here.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Related Articles